WBR0441: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "{{WBRQuestion |QuestionAuthor={{Rim}} |ExamType=USMLE Step 1 |MainCategory=Pharmacology |SubCategory=Cardiology |MainCategory=Pharmacology |SubCategory=Cardiology |MainCategor..." |
No edit summary |
||
| Line 1: | Line 1: | ||
{{WBRQuestion | {{WBRQuestion | ||
|QuestionAuthor={{Rim}} | |QuestionAuthor={{Rim}} {{Alison}} | ||
|ExamType=USMLE Step 1 | |ExamType=USMLE Step 1 | ||
|MainCategory=Pharmacology | |MainCategory=Pharmacology | ||
| Line 20: | Line 20: | ||
|MainCategory=Pharmacology | |MainCategory=Pharmacology | ||
|SubCategory=Cardiology | |SubCategory=Cardiology | ||
|Prompt=A 78 year old | |Prompt=A 78-year-old male with heart failure is brought to the emergency room with complaints of severe shortness of breath at rest. Upon evaluation, the patient is diagnosed with decompensated heart failure and is administered a recombinant B-type natriuretic peptide. Which of the following medications is most likely administered to this patient? | ||
|Explanation=[[Nesiritide]] is | |Explanation=[[Nesiritide]], a recombinant B-type natriuretic peptide, is frequently administered to reduce symptoms and left ventricular ([[LV]]) filling pressure in patients with acute [[decompensated heart failure]]. | ||
|EducationalObjectives= [[Nesiritide]], a recombinant B-type natriuretic peptide, is frequently administered to patients with [[decompensated heart failure]]. | |||
|References= Weeks SG. Nesiritide: the clinical experience. Can J Cardiol. 2008;24(Suppl B):19B-21B. | |||
Weeks SG. Nesiritide: the clinical experience. Can J Cardiol. 2008;24(Suppl B):19B-21B. | |||
|AnswerA=Digitalis | |AnswerA=Digitalis | ||
|AnswerAExp=[[Digitalis]], an inhibitor of Na/K/ATPase, indirectly causes accumulation intracellular Calcium by inactivating the Na/Ca exchanger, which requires an Na gradient to function. | |||
|AnswerAExp=Digitalis | |||
|AnswerB=Nesiritide | |AnswerB=Nesiritide | ||
|AnswerBExp=[[Nesiritide]], a B-natriuretic peptide, is frequently administered to elderly patients with [[decompensated heart failure]]. | |||
|AnswerBExp=Nesiritide | |||
|AnswerC=Sodium Nitroprusside (SNP) | |AnswerC=Sodium Nitroprusside (SNP) | ||
|AnswerCExp=[[Nitroprusside]] is a short-acting drug that increases the intracellular production of cGMP and nitrous oxide (NO). | |||
|AnswerCExp=Nitroprusside is a short-acting drug that increases the intracellular production of cGMP and nitrous oxide (NO). | |||
|AnswerD=Diazoxide | |AnswerD=Diazoxide | ||
|AnswerDExp=Diazoxide | |AnswerDExp=[[Diazoxide]], a K-channel opener, hyperpolarizes and relaxes vascular smooth muscle cells. | ||
|AnswerE=Fenoldopam | |AnswerE=Fenoldopam | ||
|AnswerEExp=Fenoldopam | |AnswerEExp=[[Fenoldopam]], a dopamine D1 receptor agonist, is frequently used to relax renal vascular smooth muscles. | ||
|RightAnswer=B | |RightAnswer=B | ||
|WBRKeyword=Nesiritide, decompensated | |WBRKeyword=Nesiritide, decompensated heart failure, natriuretic peptide, cardiovascular, cardiology, elderly, Left ventricular, heart | ||
|Approved= | |Approved=Yes | ||
}} | }} | ||
Revision as of 14:34, 23 July 2014
| Author | [[PageAuthor::Rim Halaby, M.D. [1] (Reviewed by Alison Leibowitz)]] |
|---|---|
| Exam Type | ExamType::USMLE Step 1 |
| Main Category | MainCategory::Pharmacology |
| Sub Category | SubCategory::Cardiology |
| Prompt | [[Prompt::A 78-year-old male with heart failure is brought to the emergency room with complaints of severe shortness of breath at rest. Upon evaluation, the patient is diagnosed with decompensated heart failure and is administered a recombinant B-type natriuretic peptide. Which of the following medications is most likely administered to this patient?]] |
| Answer A | AnswerA::Digitalis |
| Answer A Explanation | [[AnswerAExp::Digitalis, an inhibitor of Na/K/ATPase, indirectly causes accumulation intracellular Calcium by inactivating the Na/Ca exchanger, which requires an Na gradient to function.]] |
| Answer B | AnswerB::Nesiritide |
| Answer B Explanation | [[AnswerBExp::Nesiritide, a B-natriuretic peptide, is frequently administered to elderly patients with decompensated heart failure.]] |
| Answer C | AnswerC::Sodium Nitroprusside (SNP) |
| Answer C Explanation | [[AnswerCExp::Nitroprusside is a short-acting drug that increases the intracellular production of cGMP and nitrous oxide (NO).]] |
| Answer D | AnswerD::Diazoxide |
| Answer D Explanation | [[AnswerDExp::Diazoxide, a K-channel opener, hyperpolarizes and relaxes vascular smooth muscle cells.]] |
| Answer E | AnswerE::Fenoldopam |
| Answer E Explanation | [[AnswerEExp::Fenoldopam, a dopamine D1 receptor agonist, is frequently used to relax renal vascular smooth muscles.]] |
| Right Answer | RightAnswer::B |
| Explanation | [[Explanation::Nesiritide, a recombinant B-type natriuretic peptide, is frequently administered to reduce symptoms and left ventricular (LV) filling pressure in patients with acute decompensated heart failure. Educational Objective: Nesiritide, a recombinant B-type natriuretic peptide, is frequently administered to patients with decompensated heart failure. |
| Approved | Approved::Yes |
| Keyword | WBRKeyword::Nesiritide, WBRKeyword::decompensated heart failure, WBRKeyword::natriuretic peptide, WBRKeyword::cardiovascular, WBRKeyword::cardiology, WBRKeyword::elderly, WBRKeyword::Left ventricular, WBRKeyword::heart |
| Linked Question | Linked:: |
| Order in Linked Questions | LinkedOrder:: |